Merck (MRK) and Moderna, Inc. (MRNA), announced the initiation of INTerpath-002, a pivotal Phase 3 randomized clinical trial evaluating V940, an investigational individualized neoantigen therapy, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment in patients with completely resected Stage II, IIIA or IIIB non-small cell lung cancer. Global recruitment of the INTerpath-002 has begun, and the first patients enrolled in Australia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Merck, Eisai provide update on Phase 3 LEAP-001 trial
- Merck discontinues trial evaluating Keytruda combination in NSCLC
- Merck reports Phase 2 results of coformulation for lung cancer
- White House to back controversial patent ploy to fight drug costs, STAT says
- Curis signs agreement for emavusertib/pembrolizumab combination melanoma study